ライフサイエンスコーパス: chimerism

1 likely to ensure sustained high-level donor chimerism.

2 ong-term hematopoietic engraftment and donor chimerism.

3 sis (HLH) at the cost of more frequent mixed chimerism.

4 s were exploited to quantify donor/recipient chimerism.

5 visceral fat was independent of the level of chimerism.

6 phar1(-/-)), had significantly reduced donor chimerism.

7 l transplants to establish mixed or complete chimerism.

8 onor-specific tolerance and mixed allogeneic chimerism.

9 tudies looking at long-term lineage-specific chimerism.

10 hieving excellent survival with high myeloid chimerism.

11 ncarrier donors and achieving complete donor chimerism.

12 ability of remission for life with 90% donor chimerism.

13 ing an individual with genome-wide suspected chimerism.

14 biotic gene transfer would lead to inherited chimerism.

15 nts and was associated with higher donor CD3 chimerism.

16 late development, thus limiting the cost of chimerism.

17 details on CMV infection episodes and T-cell chimerism.

18 fluence of B cell depletion on hematopoietic chimerism.

19 s by induction of stable hematopoietic mixed chimerism.

20 al-transplant recipients with haematopoietic chimerism.

21 be achieved after the establishment of mixed chimerism.

22 te immunocompetence, and no peripheral blood chimerism.

23 including tolerance induction through mixed chimerism.

24 approach for attaining stable hematopoietic chimerism.

25 cing transplantation tolerance through mixed chimerism.

26 sents an obstacle to successful induction of chimerism.

27 was successful in all patients with durable chimerism.

28 ans through the induction of transient donor chimerism.

29 nal allograft TOL induced by transient mixed chimerism.

30 me donor for both grafts and documented full chimerism.

31 nd 116, despite the development of excellent chimerism.

32 imerism and three (18%) had mixed donor-host chimerism.

33 the establishment of transient or persistent chimerism.

34 tissue mass than animals with high levels of chimerism.

35 ans through the induction of transient mixed chimerism.

36 odified to evaluate engraftment, assessed by chimerism.

37 or recipient-specific HLA marker to analyze chimerism.

38 ll chimerism and low B-cell and myeloid cell chimerism (0% to 46%).

39 ents who successfully developed multilineage chimerism, 10 achieved long-term immunosuppression-free

40 ll treated animals revealed peripheral blood chimerism (4 weeks), most pronounced after repetitive ce

41 posttransplantation cyclophosphamide after a chimerism-ablating secondary recipient lymphocyte infusi

42 either mixed hematopoietic or CD8(+) T cell chimerism, above which immune regulation was reestablish

43 The levels of donor cell chimerism achieved in this study would be therapeutic fo

44 induce tolerance through mixed hematopoietic chimerism across a pig-to-primate barrier.

45 Hematopoietic chimerism after allogeneic bone marrow transplantation m

46 afts from all mice and benefit from enhanced chimerism after BCNU with less cell infiltrate and no ch

47 it in normal bone marrow cells and increases chimerism after bone marrow transplantation, indicating

48 Finally, conversion to donor chimerism after donor lymphocytes is associated with cli

49 We prospectively studied the kinetics of LC-chimerism after sex-mismatched allogeneic hematopoietic

50 o 50%), durable, donor-derived hematopoietic chimerism after transplantation of 20 million total bone

51 or unrelated donor recipients had full donor chimerism, all 3 recipients of mismatched unrelated dono

52 Chimerism analysis of isolated CMV tet(low) and tet(high

53 itor transplant and HIV infection, including chimerism analysis, CCR5 genotyping and viral tropism, v

54 ement that there was a higher rate of B-cell chimerism and a lower number of patients who required on

55 Cell-based therapies to facilitate chimerism and achieve tolerance in major histocompatibil

56 atients have predominantly or complete donor chimerism and adequate immune recovery and are free of a

57 ) cells promotes durable mixed hematopoietic chimerism and allograft tolerance in mice receiving allo

58 recipients have better B-lymphocyte/myeloid chimerism and are free from immunoglobulin replacement t

59 ndent on the previous establishment of mixed chimerism and can be induced coincident with hematopoiet

60 ls required to achieve durable hematopoietic chimerism and donor-specific skin allograft tolerance an

61 ies of the fetus to achieve mixed allogeneic chimerism and donor-specific tolerance (DST).

62 We sought to analyze long-term chimerism and event-free survival in children undergoing

63 ts for maintenance of minimal posttransplant chimerism and for therapeutic strategies involving gene

64 Mixed chimerism and graft-versus-host-disease (GVHD) remain li

65 Twelve have achieved stable donor chimerism and have been successfully taken off immunosup

66 We previously showed full donor chimerism and immunosuppression withdrawal in highly mis

67 rmediate hPSC type exhibits higher degree of chimerism and is able to generate differentiated progeni

68 d donor HSCT had high levels of donor T-cell chimerism and low B-cell and myeloid cell chimerism (0%

69 Chimerism and mixoploidy are defined by the presence of

70 ines during development is a likely cause of chimerism and mixoploidy in mammals.

71 ollowing IUHCT can be enhanced to high-level chimerism and near complete Hb replacement with normal d

72 ssion medication with continued stable donor chimerism and no graft-vs-host disease.

73 of either CD8(+) DCs or NKT cells abrogated chimerism and organ graft acceptance.

74 ed expression of Hmga2 resulted in increased chimerism and platelet counts in recipients of retrovira

75 chimerism compared with models of postnatal chimerism and provides additional support for the prenat

76 8 blockade induces multi-lineage, full donor chimerism and recipient-specific tolerance while maintai

77 Correlation between chimerism and rejection, graft failure, and patient surv

78 mphocytes and was sufficient to induce mixed chimerism and robust systemic tolerance across full majo

79 d and high levels of multilineage allogeneic chimerism and robust tolerance to the donor.

80 mmune response associated with conversion of chimerism and severe GVHD.

81 ses and thereby enhanced donor hematopoietic chimerism and T cell deletion after bone marrow transpla

82 in the AfuTmV-1 genome is a striking case of chimerism and the first example (to our knowledge) of su

83 2V617F(+) Moreover, the degree of human cell chimerism and the proportion of malignant donor cells we

84 13 (76%) of 17 patients achieved full donor chimerism and three (18%) had mixed donor-host chimerism

85 d a new therapeutic approach to induce mixed chimerism and tolerance by a direct pharmacological modu

86 Unexpectedly, chimerism and tolerance were established in old recipien

87 relevant methods for inducing hematopoietic chimerism and transplantation tolerance, with a special

88 y be complicated by the development of mixed chimerism and uncertainty regarding the risk of HLH recu

89 Barcoded HSCs showed robust (>80% human chimerism) and reproducible myeloid and lymphoid engraft

90 version of mixed chimerism toward full donor chimerism, and a potentially favorable balance between G

91 s in the absence of haematopoietic-stem-cell chimerism, and can rescue an adult-onset osteopetrotic p

92 w risk of acute GVHD, a higher risk of mixed chimerism, and delayed early lymphocyte recovery and tha

93 D, achievement of at least 90% myeloid donor chimerism, and incidence of graft failure after at least

94 alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following RIC HCT wit

95 lant alemtuzumab levels on acute GVHD, mixed chimerism, and lymphocyte recovery.

96 egulatory T-cell induction, peripheral blood chimerism, and microchimerism in lymphatic organs were a

97 life, manifests as constitutional mosaicism, chimerism, and mixoploidy in live-born individuals.

98 es, longitudinal immunoreconstitution, donor chimerism, and quality of life (QoL) of IL2RG/JAK3 SCID

99 ng transplant recipients, with 3 patterns of chimerism apparent: transient, intermediate, and persist

100 induce allograft tolerance through the mixed chimerism approach using a conditioning regimen with aCD

101 nal or islet allograft tolerance via a mixed chimerism approach.

102 served in tolerant recipients with our mixed chimerism approach.

103 Detailed genotyping implicates chimerism arising at the juncture of zygotic division, t

104 accelerate acquisition of full donor T-cell chimerism as a tractable strategy to improve outcomes in

105 t mice decreased the degree of donor-derived chimerism as well as the JAK2V617F allele burden, indica

106 complementation and human-mouse interspecies chimerism assays.

107 9 patients treated at Stanford who had mixed chimerism-associated CLL relapse, 4 (44%) converted to f

108 Acquisition of full donor T-cell chimerism at 3 months abrogated the adverse impact of pr

109 ll animals revealed peripheral multi-lineage chimerism at four weeks (P < 0.01) independent of cell t

110 anscriptome data to determine host and donor chimerism at single-cell resolution from bone marrow mon

111 ransplantation with a particular emphasis on chimerism-based approaches.

112 It explains the basic mechanisms of chimerism-based tolerance and provides an update on ongo

113 cells (BMCs) has been demonstrated in mixed chimerism-based tolerance induction protocols; however,

114 vestigated the impact of immunosenescence on chimerism-based tolerance induction.

115 By contrast, transient chimerism-based tolerance is devoid of GVHD risk and app

116 d leukemia (AML) who converted to full-donor chimerism but developed severe acute GVHD after prophyla

117 l as host Tregs did not affect hematopoietic chimerism but it led to rapid loss of skin allografts.

118 showed a high degree of passenger leukocyte chimerism by immunohistochemistry and flow cytometry.

119 terspecies fetuses with high levels of organ chimerism can be generated via blastocyst complementatio

120 We recently reported that durable chimerism can be safely established in mismatched kidney

121 autoreactive T cells, and induction of mixed chimerism can effectively reverse these defects.

122 r studies indicate that MHC-mismatched mixed chimerism can mediate thymic deletion of cross-reactive

123 Multilineage chimerism, clonal deletion, and lymphocyte subsets were

124 Thus, we conclude that endothelial chimerism combined with vascular sequestration of DSAs p

125 of allospecific tolerance in prenatal mixed chimerism compared with models of postnatal chimerism an

126 ent coverage uniformity and markedly reduced chimerism compared with products of liquid MDA reactions

127 t and resulted in significantly higher donor chimerism compared with recipients conditioned with TGF-

128 MT in four patients with more than 95% donor chimerism, consistent with a 2.06-2.54 log(10) reduction

129 e to neutrophil recovery and extent of donor chimerism correlated significantly with time to contrast

130 Hematopoietic recovery and chimerism, cumulative density of infections, nonrelapse

131 The minimum level of donor chimerism (DC) required to prevent HLH reactivation in h

132 Two subjects with only transient chimerism demonstrated subclinical rejection on protocol

133 f CIs induced long-term germline and somatic chimerism, demonstrating self-renewal and pluripotency o

134 Therefore, induction of MHC-mismatched mixed chimerism depletes pre-existing and de novo-developed au

135 In subsequent patients, chimerism detection ranged from 49 days to >14 years.

136 Subjects with persistent chimerism developed few serious infections when off IS.

137 HIV-1 correlated temporally with full donor chimerism, development of graft-versus-host disease, and

138 patients experienced declining donor myeloid chimerism (DMC) levels with eventual return of disease.

139 Chimerism endows colonies with increased virulence and a

140 CLL relapse, 4 (44%) converted to full donor chimerism following ibrutinib initiation, in association

141 atal "boosting" strategy; and (3) high-level chimerism following IUHCT and postnatal "boosting" resul

142 he murine SCD and Thal models; (2) low-level chimerism following IUHCT can be enhanced to high-level

143 itor colonies and peripheral blood leukocyte chimerism following transplantation into conditioned hos

144 Finally, we describe the kinetics of chimerism for several lymphocyte populations as well as

145 w cells, compared with <= 2.1% hematopoietic chimerism from 50 million total bone marrow cells withou

146 ier, namely thymus transplantation and mixed chimerism, from their inception in rodent models through

147 ogeneic or (hostXdonor)F1-Tcm, support donor chimerism (> 6 months) in sublethally irradiated (5.5Gy)

148 complete donor chimerism or high-level mixed chimerism (>50% donor chimerism) in all lineages.

149 r transient or sustained lymphohematopoietic chimerism has been demonstrated in several preclinical a

150 Donor chimerism has been maintained at 99% in peripheral T cel

151 erity, time to engraftment, lineage-specific chimerism, immune reconstitution, and discontinuation of

152 infusion resulted in a significant change of chimerism in 1 of 3 male recipients without any signs of

153 clinically relevant levels of hematopoietic chimerism in a canine model of maternal-to-fetal IUHCT.

154 ovel approach to accurately define leukocyte chimerism in a complex organ such as a transplanted kidn

155 Treg cell BMT that were evaluable displayed chimerism in all lineages, including T cells, for up to

156 nsplant tolerance has been achieved by mixed chimerism in animal models and in a limited number of ki

157 VCA tolerance, and the kinetics of cutaneous chimerism in both of these populations in VCAs transplan

158 Blood spot DNA from this subject displayed chimerism in CSF1R acquired after haematopoietic stem ce

159 e recipient demonstrated 3% donor lymphocyte chimerism in her peripheral blood immediately before HSC

160 The level and duration of chimerism in liver recipients were comparable to those p

161 nditioning plus FCRx safely achieved durable chimerism in mismatched allograft recipients.

162 social interaction, particularly by reducing chimerism in multicellular fruiting bodies that develop

163 eved after induction of only transient mixed chimerism in nonhuman primates (NHPs) and humans.

164 s across thousands of cells revealed genetic chimerism in patients after bone marrow transplantation

165 The cumulative incidence of mixed chimerism in patients with an alemtuzumab level </=0.15

166 lls sustained significantly higher levels of chimerism in primary and secondary recipients than CD166

167 angerin-staining was used to assess donor LC-chimerism in skin biopsies obtained on days 28, 56, and

168 We used mixed hematopoietic chimerism in the canine model of major histocompatibilit

169 rsist long-term, contribute to multi-lineage chimerism in the circulation, and result in T cell toler

170 Conversion of chimerism in the presence of GVHD after CD4 donor lympho

171 The change in chimerism in the recipient occurred in association with

172 TBI dose capable of achieving complete donor chimerism in this mouse strain combination was 325 cGy g

173 fe (cure) is 98% in the context of 80% donor chimerism in total HIV target cells and greater than 99%

174 sm or high-level mixed chimerism (>50% donor chimerism) in all lineages.

175 end points were the level of donor leukocyte chimerism; incidence of acute and chronic graft-vs-host

176 in controls; both myeloid and lymphoid cell chimerism increased because of higher engraftment of HSC

177 ecule Bcl-2 inhibitor ABT-737 promoted mixed chimerism induction and reversed the antitolerogenic eff

178 istic underpinning for the susceptibility to chimerism induction despite increased TMEM frequencies.

179 Sustained T-cell chimerism is a more robust biomarker of tolerance than d

180 splantation.Induction of mixed hematopoietic chimerism is a robust approach to establishing such tran

181 Mixed chimerism is associated with allograft acceptance and to

182 rospective study confirmed that induction of chimerism is essential for long-term immunosuppression-f

183 long-term HIV reservoir when complete donor chimerism is established.

184 Hematopoietic chimerism is known to promote donor-specific organ allog

185 Although induction of durable mixed chimerism is required for murine skin allograft toleranc

186 lative HSC transplants (HSCTs), stable mixed chimerism is sufficient to reverse the disease.

187 Enhanced mixed chimerism leads to long-term donor-specific allograft to

188 urvival, which best correlates with lymphoid chimerism levels higher than 3.1%.

189 aracteristic analyses revealed that lymphoid chimerism levels of 3.1% or greater could reliably predi

190 High chimerism levels were induced across multiple hematopoie

191 Chimerism levels were significantly higher in treated pu

192 level was 48% (95% CI, 34%-62%); the myeloid chimerism levels, 86% (95% CI, 70%-100%).

193 of the recipients that failed to develop any chimerism lost their allografts due to TCMR after discon

194 imens were more likely to have donor myeloid chimerism <50% early after HCT.

195 ients ended up with very low levels of donor chimerism (<10% donor), especially in the myeloid lineag

196 tance had established higher levels of donor chimerism, lymphocyte responses which were attenuated to

197 some cells, whether achieved by mosaicism or chimerism, may confer benefit in hereditary diffuse leuk

198 nt studies suggest that MHC-mismatched mixed chimerism mediates negative selection of autoreactive th

199 matched H-2(b) but not matched H-2(g7) mixed chimerism mediates thymic deletion of the cross-reactive

200 ere, we investigated in mice whether durable chimerism might be enhanced by pre-treatment of the reci

201 achieved using MGMT transgenic BM in a mixed-chimerism model receiving BCNU across a major histocompa

202 All patients, including those with mixed chimerism, mounted robust antibody responses to vaccinat

203 Given the full chimerism, no immunosuppressive agent was prescribed exc

204 recipients with an average level of initial chimerism of 11.7% (range 3% to 39%) without conditionin

205 hereas heart macrophages showed a much lower chimerism of 2.7+/-0.5% (P<0.01).

206 After 6 weeks, we observed blood monocyte chimerism of 35.3+/-3.4%, whereas heart macrophages show

207 splantation often results in long-term mixed chimerism of donor and recipient blood in transplant pat

208 ce pluripotency, but did selectively enhance chimerism of MiP-derived tissue in both fetal and adult

209 ations show decreased peripheral and central chimerism of PHD2-deficient cells but not of the most pr

210 donor-derived erythrocytes and stable mixed chimerism of recipient-derived and donor-derived leucocy

211 oductive adaptations, including hematopoetic chimerism of siblings, suppression of reproduction in no

212 In a primitive chordate model of natural chimerism, one chimeric partner is often eliminated in a

213 all surviving patients, either stable mixed chimerism or full donor chimerism were observed.

214 than 90% of patients achieved complete donor chimerism or high-level mixed chimerism (>50% donor chim

215 either simultaneously to induction of mixed chimerism or into established mixed chimeras 85-150 days

216 w Transplantation guidelines without loss of chimerism or rejection.

217 re limited either by loss of long-term mixed chimerism or risk of graft-versus-host disease (GVHD).

218 The chimerism or the beneficial graft-versus-leukemia respon

219 rapy did not affect the degree of human cell chimerism or the proportion of malignant donor cells.

220 Full-donor chimerism (P = .039) and normal enzyme levels (P = .007)

221 ansduced hCB cells as long as human platelet chimerism persisted.

222 ncrease after dUCBT, and early CD4(+) T-cell chimerism predicts for graft predominance.

223 These data show the transient chimerism protocol does not induce tolerance to livers,

224 pothesis that the renal transplant transient chimerism protocol would induce liver tolerance.

225 After T-Rapa cell infusion, mixed donor/host chimerism rapidly converted, and there was preferential

226 Peripheral blood chimerism, recipient immune reconstitution, liver functi

227 eatment was associated with early failure of chimerism, regardless of Treg cell administration.

228 Donor cell chimerism remained stable for up to 2 years and was asso

229 es complexity modeled on a real counterpart, chimerism remained within the same species for most cont

230 To better define the level/duration of chimerism required for stable renal allograft TOL, we re

231 report whether approaches resulting in mixed chimerism result in clinically relevant immune reconstit

232 Importantly, this chimerism resulted in successful donor skin acceptance,

233 Induction of MHC-mismatched mixed chimerism results in depleting host-type pre-existing pr

234 Induction of mixed hematopoietic chimerism results in donor-specific immunological tolera

235 compatibility complex (MHC)-mismatched mixed chimerism reversed autoimmunity and reestablished thymic

236 In patients with mixed chimerism, selective advantage for donor-derived T cells

237 a high-fat-diet, animals with low levels of chimerism showed a significantly lower adipose tissue ma

238 ic T-cell numbers and select cells to assess chimerism status in a subset of R+/D- and R+/seropositiv

239 infections, and significantly influence the chimerism status toward recipients.

240 immunity and might therefore also influence chimerism status.

241 However, these mixed-chimerism strategies were limited either by loss of long

242 A skin biopsy and chimerism study should be performed whenever possible.

243 At high levels of chimerism such protocols can permit central deletional t

244 of T cell progenitors, BMCs increased donor chimerism, T cell generation and antigen-specific T cell

245 Cs led to higher donor-derived hematopoietic chimerism than GABRR1-positive (GR+) HSCs.

246 as and generated chimeras with a higher skin chimerism than those derived from fiPSC.

247 ity of EVs and the existence of interspecies chimerism that characterizes the novel variants in the c

248 ntraspecies and mouse/rat interspecies donor chimerism that continuously increases from embryonic day

249 In the two patients with less than 95% donor chimerism, the HIV latent reservoir remained stable.

250 Upon cord blood full chimerism, the patient's CCR5 Delta32 homozygous CD4 T c

251 Hematopoietic chimerism, the stable coexistence of host and donor bloo

252 zed composite allotransplantation (VCA) with chimerism through bone marrow transplantation (BMT) are

253 a/Fc, or IL-10/Fc fusion proteins to promote chimerism to induce tolerance.

254 signed to reveal the mechanisms on how mixed chimerism tolerizes autoreactive B cells in T1D.

255 NOD mice, but it is still unclear how mixed chimerism tolerizes autoreactive B cells.

256 h2/Th1 cytokine profile, conversion of mixed chimerism toward full donor chimerism, and a potentially

257 obin expression/VCN and enhanced early human chimerism under nonmyeloablative conditions, thus repres

258 Chimerism under yet lower irradiation (4.5Gy) was achiev

259 ed immune regulation in the context of mixed chimerism using a murine model of HLH.

260 Prolongation of transient porcine chimerism via transgenic expression of human CD47 in a p

261 em cell source, toxicity, engraftment, GVHD, chimerism, viral reactivation, post-HSCT complications,

262 sed immunoglobulin replacement, T-lymphocyte chimerism was 50% or greater donor in 85.2%.

263 Donor chimerism was achieved in 20% of recipients conditioned

264 Xenogeneic peripheral blood chimerism was assessed after each infusion.

265 Chimerism was associated with the generation of regulato

266 When split cell chimerism was available, 95% or more myeloid donor chime

267 - and B-cell immune reconstitution and donor chimerism was compared between the NK(+) (n = 24) and NK

268 The degree of donor LC-chimerism was correlated with the development of skin GV

269 In the initial patient, hematopoietic chimerism was detectable for only 105 days after the tra

270 Mixed chimerism was detected in peripheral blood at 1 month af

271 Stable (>/=90%) myeloid donor chimerism was documented in 52 (93%) surviving patients.

272 ism was available, 95% or more myeloid donor chimerism was documented in 80% of surviving patients.

273 Donor chimerism was durable, multilineage, and stable.

274 torically performed sequentially after donor chimerism was established.

275 ogeneic HSCT, the rate of stable mixed-donor chimerism was high and allowed for complete replacement

276 Donor chimerism was indispensable for sustained tolerance, as

277 Accordingly, mixed chimerism was induced in NOD mice through radiation-free

278 uction has been extended to patients in whom chimerism was intentionally induced at the time of kidne

279 n peripheral blood at 1 month after VCA, but chimerism was lost in all transplant recipients by 4 mon

280 Chimerism was lost in three patients at 2, 3, and 6 mont

281 Deletion did not persist when chimerism was lost.

282 was delayed by two months, and full donor LC-chimerism was only reached by day 84 after transplant.

283 Complete IS drug withdrawal without chimerism was reported in a prospective trial of liver t

284 e maximum level but not duration of lymphoid chimerism was significantly higher in TOL recipients com

285 On the other hand, the maximum myeloid chimerism was significantly higher in TOL than in TCMR (

286 mixed chimerism, without significant T cell chimerism, was achieved in the animals that received BMT

287 Latest median donor myeloid and lymphocyte chimerism were 100% (range, 0-100) and 100% (range, 64-1

288 B-lymphocyte and myeloid chimerism were highly correlated (rho, 0.98; P < .001).

289 type of conditioning, and presence of mixed chimerism were not.

290 either stable mixed chimerism or full donor chimerism were observed.

291 d levels and duration of myeloid or lymphoid chimerism were retrospectively analyzed in 34 NHP combin

292 The level and duration of transient chimerism were substantially greater in baboons receivin

293 itted establishment of durable hematopoietic chimerism when the mice were given a low dose of donor B

294 ompared with naive T cells to increase donor chimerism when transferred to quiescent mixed allogeneic

295 All 3 CIKTx recipients developed mixed chimerism, which was significantly superior to that obse

296 d were comparable to subjects with transient chimerism who underwent autologous reconstitution.

297 2%, P < .01) and had high-level donor T-cell chimerism with superior long-term recovery of CD4 T-cell

298 High-level mixed chimerism without GVHD can be achieved using MGMT transg

299 Tolerance induction by mixed chimerism without toxic conditioning and with a low risk

300 Transient mixed chimerism, without significant T cell chimerism, was ach